Abnormal hemoglobin H band in myelodysplastic syndromes (MDS): A case report

被引:2
|
作者
Liu, Cong [1 ]
Zou, Cuicui [1 ]
Zou, Shuhui [1 ]
Wang, Qun [2 ]
Xiao, Dejun [1 ]
Zhang, Liqin [1 ]
机构
[1] Ganzhou Peoples Hosp, Ganzhou 341000, Jiangxi, Peoples R China
[2] Luneng Biotechnol Shenzhen Co LTD, Shenzhen 518000, Peoples R China
关键词
Myelodysplastic syndrome; Abnormal hemoglobin H band; ACUTE MYELOID-LEUKEMIA; SIDEROBLASTIC ANEMIA; ALPHA-THALASSEMIA; INACTIVATION; CYTOGENETICS; EXPRESSION; SURVIVAL; CHILDREN; GENE;
D O I
10.1016/j.tracli.2020.10.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Myelodysplastic syndrome (MDS) is a group of heterogeneous diseases derived from hematopoietic stem cells characterized by hemolytic anemia and high risk of conversion to acute leukemia. MDS is an age-related disease in which approximately 80% of patients are over 60years of age, male and female. Anemia is the most common clinical condition, and many patients are also associated with infection and bleeding. When the amount of alpha globin synthesis is insufficient, the remaining beta chain forms tetramer beta 4, i.e. HbH. The latter forms a precipitate in red blood cells, leading to hemolytic anemia, called HbH disease, the majority of which is congenital, a small number of patients with myelodysplastic syndrome and acute myeloid leukemia may appear HbH (called acquired HbH disease). We reported a 71years old male patient diagnosed as myelodysplastic syndromes (MDS) in our hospital. The patient has a negative alpha-thalassemia gene test. The H band is detected by hemoglobin electrophoresis. This article analyzed and discussed this case with MDS, as well reviewed MDS. (C) 2020 Published by Elsevier Masson SAS on behalf of Societe francaise de transfusion sanguine(SFTS).
引用
收藏
页码:206 / 210
页数:5
相关论文
共 50 条
  • [1] Myelodysplastic syndromes (MDS)
    Reinhard Stauder
    memo - Magazine of European Medical Oncology, 2009, 2 (2) : 108 - 109
  • [2] Myelodysplastic syndromes (MDS)
    Stauder, R.
    MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2009, 2 (02) : 108 - 109
  • [3] Myelodysplastic syndromes (MDS)
    Germing, U.
    Kuendgen, A.
    Haas, R.
    Gattermann, N.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2012, 137 (05) : 183 - 185
  • [4] Myelodysplastic syndromes (MDS)
    Burgstaller S.
    memo - Magazine of European Medical Oncology, 2014, 7 (3) : 134 - 137
  • [5] Case report - Use of iron chelate therapy for patients with myelodysplastic Syndromes (MDS)
    Girrbach, Gudrun
    ONKOLOGIE, 2007, 30 (10): : 525 - 525
  • [6] Update on myelodysplastic syndromes (MDS)
    Hector Rodriguez, Jose
    del Lujan Acosta, Irma
    REVISTA MEDICA DE ROSARIO, 2011, 77 (01): : 24 - 41
  • [7] Rigosertib in myelodysplastic syndromes (MDS)
    Raza, A.
    Ali, A. M.
    Reddy, M. V. R.
    Hoffman, B. S.
    Petrone, M. E.
    Maniar, M.
    Pinheiro, R. F.
    Coutinho, D. F.
    Fruchtman, S. M.
    EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (09): : 981 - 988
  • [8] The pathogenesis of myelodysplastic syndromes (MDS)
    Platzbecker, Uwe
    Meredyth-Stewart, Michelle
    Ehninger, Gerhard
    CANCER TREATMENT REVIEWS, 2007, 33 : S53 - S58
  • [9] Myelodysplastic syndromes (MDS) Preface
    Klimek, Virginia
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2015, 28 (01) : 1 - 2
  • [10] Patients with myelodysplastic syndromes (MDS) often mobilise abnormal haemopoietic progenitors.
    Mijovic, A
    Howard, J
    Czepulkowski, B
    Pagliuca, A
    Mufti, GJ
    BONE MARROW TRANSPLANTATION, 1999, 23 : S153 - S153